Abstract: There are provided HPMCAS (hypromellose acetate succinate) having such a property that a solution of the HPMCAS in a solvent has a controlled viscosity; and a method for producing the HPMCAS. More specifically, provided are HPMCAS having such property that a solution of 10 parts by weight of the HPMCAS in 100 parts by weight of a mixed solvent having a weight ratio of methylene chloride to methanol of 1:1 has a viscosity at 20° C. of 135 mPa·s or less; and a method for producing the HPMCAS including an esterification step of adding acetic anhydride and succinic anhydride to a solution of hypromellose in glacial acetic acid in the presence of sodium acetate to obtain a reaction product mixture, wherein the succinic anhydride is added intermittently, and a precipitation step of mixing the reaction product mixture with water to precipitate the HPMCAS.

Abstract: A cryogel which includes lignin nanoparticles embedded in crosslinked gelatin. The cryogel is formed at subfreezing temperatures where aggregation of polymerized or crosslinked materials is prevented by ice crystals. When thawed, the cryogel is a densely crosslinked microporous composition with a plurality of pores ranging from 50-150 ?m in size. The cryogel combines a natural bio waste polymer in the form of lignin together with a collagen derived natural polymer. Incorporation of lignin within gelatin improves the mechanical performance of the cryogel and enhances its shape recovery rate. The macropororous composition inhibits growth of both gram positive and gram negative bacteria. In addition, the macoporous composition exhibits excellent free radical scavenging activity. All of the properties make the cryogel an excellent material for wound healing and tissue engineering applications.

Abstract: Extended release pyridostigmine dosage forms, suitable for maintaining stable plasma concentrations with reduced or minimized initial burst release/dose dumping of pyridostigmine, are provided. The dosage forms include matrix tablets, gastroretentive tablets, and pellets, the latter being suitable for dosing in capsules, tablets, and sachets, as well as for sprinkling on foodstuffs. The disclosure also provides methods for improving patient compliance by administering once-a-day extended release pyridostigmine bromide dosage forms that provide a superior controlled drug release.

Abstract: The present disclosure relates to an antiperspirant composition for a roll-on application comprising a) at least one antiperspirant active substance including an inorganic or organic salt of aluminum, zirconium or a mixture thereof, b) a rice starch and c) a hydrophobically modified clay mineral. Furthermore, the present disclosure relates to a roll-on applicator including a composition as contemplated herein, and a non-therapeutic use of a composition as contemplated herein.

Abstract: The present invention provides a method for treatment or prevention of a disease associated with a decrease in bone mass comprising administering to a subject in need of such treatment a composition comprising an effective amount of genistein phosphate conjugate. The present invention also provides a method of improving bone architecture and bio-mechanical strength of bone comprising administering to a subject in need of such treatment of a composition comprising an effective amount of genistein phosphate conjugate. The present invention administering to a subject in need of such treatment a composition comprising an effective amount of genistein phosphate conjugate can effectively increase the oral bioavailability so as to reduce the symptoms and the risk of complications of menopausal women, increase bone mineral content, bone density and bio-mechanical strength of bone, and slow down osteoporosis.

Abstract: In some aspects, the present invention provides compositions and methods of treatment comprising long-acting compstatin analogs. In some aspects, long-acting compstatin analogs comprise a clearance-reducing moiety attached to two compstatin analog moieties, wherein each compstatin analog moiety comprises a cyclic peptide comprising the amino acid sequence as set forth in SEQ ID NO: 28 extended by a lysine residue or a sequence comprising a lysine residue at the N-terminus, C-terminus, or both, wherein the lysine residue is separated from the cyclic portion of the peptide by a spacer comprising 8-amino-3,6-dioxaoctanoic acid (AEEAc) moiety, the clearance reducing moiety comprises a polymer, wherein each end of the polymer is linked to one of the compstatin analog moieties by way of a linker moiety that is or comprises a carbamate, and wherein the polymer is a PEG having an average molecular weight of about 40 kDa.

Abstract: The present invention relates to a composition and method for stabilisation of compounds including retinoids using the synergistic effects of beta-carotene and sodium polyaspartate.

Abstract: Polyphosphazenes polyelectrolytes. The polyphosphazenes can be prepared by substituting pendant groups (e.g., ionic groups or pendant groups that can form ionic groups) onto a reactive macromolecular precursor for example, by reaction between the reactive chlorine atoms on the backbone of poly(dichlorophosphazene) and appropriate organic nucleophiles. In certain examples, one or more charged pendant groups of a polyphosphazene is/are further modified to introduce desired counterions, which can be hydrophobic counterions. The polyphosphazenes can activate distinct Toll-Like Receptors (TLRs) and can be used in methods of stimulating an immune response.

Abstract: A method for treating wastewater containing fluoroquinolone antibiotics by activating peroxyacetic acid heterogeneously with lanthanum ruthenate perovskite (LaRuO3) catalyst. The method includes: adding peroxyacetic acid to wastewater containing ciprofloxacin, mixing to obtain a peroxyacetic acid solution, adjusting a pH of the peroxyacetic acid solution; and adding lanthanum ruthenate perovskite to the peroxyacetic acid solution to obtain a mixed solution, and stirring the mixed solution in a constant temperature shaker, and removing the ciprofloxacin at a normal temperature.

Abstract: A biocompatible membrane comprised of alginate and hyaluronate. The membrane may be used to prevent unwanted scarring after surgery. The tissue adherence and the rate of bioresorption of the membrane may be modified through an external stimulus comprising a sequestering agent and a viscosity modifier.

Abstract: The present disclosure provides methods of treating defects such as wrinkles or scars via a subdermal injection of placental tissue components. It also provides placental tissue compositions maintained within the barrel of a syringe, which may be for use in treating such defects.

Abstract: The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject. The disclosure further provides therapeutic treatment regimens designed to reduce or inhibit AD A or unwanted immune cell activation (e.g., B cell activation, cytokine secretion) in a subject being treated with mRNA-based therapeutics.

Abstract: Described herein are stable orally disintegrating tablets containing a proton pump inhibitor, methods for making the same, and methods for treating subjects in need thereof. In particular, the orally disintegrating tablets are composed of a plurality of coated units admixed with a disintegrant that demonstrate decreased friability and increased hardness.

Abstract: A system for integrating an application within a virtual reality presentation invokes the virtual reality presentation in a virtual reality presentation device. The virtual reality presentation is an instance of a virtual reality application executing in the virtual reality presentation device. The system invokes the application within a non-virtual reality application environment. The system integrates the application within the virtual reality presentation by rendering an instance of the application as a virtual window layered on the virtual reality presentation. The system renders a list of applications within the virtual reality presentation device. The system receives, from a user, a selection from the list, and integrates the selected application within the virtual reality presentation by rendering a respective instance of the selected application as a respective virtual window layered on the virtual reality presentation.

Abstract: An improvement on a method and device of the first wearable device that increases muscle strength using a holding device containing nutrients. This invention is detailed in U.S. Pat. Nos. 8,617,590, 9,636,310, 9,510,988. With the addition of a light source module and/or a vibrating module and/or a magnetic module to this holding device, it has been found that the resulting device has a surprising and unexpected synergistic effect on muscle strength. This phenomenal increase in muscle strength translates into improved athletic performance. The resulting holding device may be in the form of a belt, locket headband, wrist band, ankle band, pedal device, helmet, or gloves.

Abstract: Described herein are compositions that include hypochlorite and methods of alleviating, ameliorating, palliating, reducing, or treating a traumatic brain injury or neurological disorder, such as a concussion, with such composition. The composition may further include a salt, a buffer, a rheology agent, or a silicone polymer or blend thereof. The salt may include halite, table salt, common salt, curing salt, flake salt, Epsom salt, sea salt, Alaea salt (or Hawaiian sea salt), Alpenbergkern salt, Anglesey Sea salt, Dead Sea salt, Himalayan sea salt, Kalahari salt, Maras salt, Murray River salt flakes, Namibian salt pearls, Persian blue fine salt, Polish mine salt, primordial sea salts, Sal de Tavira, Sale Marino di Trapani, Sel de Guérande, South African Sea salt, Utah salt, black lava salt, brine, rock salt, red rock salt, or kosher salt, or combinations thereof.

Abstract: The present invention relates to artificial tear compositions and ophthalmic compositions suitable for drug delivery. In one embodiment of the present invention, the compositions comprise a galactomannan polymer such as guar or hydroxypropyl guar, hyaluronic acid, and a cis-diol such as sorbitol. In a preferred embodiment, the compositions also comprise a borate compound.

Abstract: An antifouling thermoplastic polyurethane (TPU) composition comprises a thermoplastic polyurethane and an organometallic antifouling additive and has a surface energy of from about 18 to about 26 mJ/m2. An article which is resistant to adhesion of organisms comprises the antifouling thermoplastic elastomer (TPU) composition having a surface with a 3-dimensional surface topography.

Abstract: A method for preparing a degradable magnesium-containing calcium phosphate-calcium sulfate porous composite biological scaffold by subjecting a calcined bovine cancellous bone mineral porous scaffold to a treatment using a ternary system containing a magnesium source, a sulfur source and a phosphorus source, taking out and drying, and subjecting to a high-temperature calcination. The degradable magnesium-containing calcium phosphate-calcium sulfate porous composite biological scaffold has good three-dimensional interconnected mesh structure, osteoconductivity, degradability, good mechanical strength and biocompatibility, simultaneously. At the same time, calcium sulfate whiskers with larger length-diameter ratio grow in the mesh, thereby increasing the specific surface area of the material and possibly improve the adhesion of cells.

Abstract: A process for producing a calcium phosphate reactant, according to which: in a first step, use is made of a source of calcium and a source of phosphate ions in water, in a molar ratio that is adjusted so as to obtain a Ca/P molar ratio of between 0.5 and 1.6, and the source of calcium is reacted with the phosphate ions at a pH of between 2 and 8, in order to obtain a suspension (A) of calcium phosphate, and in a second step, added to the suspension (A) are an alkaline compound comprising hydroxide ions in order to set a pH of more than 8 and an additional source of calcium in order to obtain a suspension (B) of calcium phosphate reactant having a Ca/P molar ratio of more than 1.6. A calcium phosphate reactant obtainable by such a process.

Abstract: The invention pertains to a solid dosage form comprising vigabatrin; a superdisintegrant, advantageously chosen from the list consisting of crospovidone, a cellulose derivative and a starch derivative; a non-reducing sugar, advantageously chosen from the list consisting of mannitol, xylitol, and sorbitol; and a stearate derivative, advantageously a stearate or stearyl fumarate salt, more advantageously sodium stearyl fumarate or magnesium stearate.

Abstract: An extract obtained from Saxifraga sp., Astrantia major, or a combination thereof and a method of treating or relieving an inflammatory-skin related condition in a subject is provided. The method comprises administering or applying a composition comprising an effective amount of an extract from Saxifraga sp., Astrantia major or a combination thereof, and a carrier, wherein the effective amount of the extract inhibits tumor necrosis factor alpha and Interleukine-1beta activity. The inflammation may be inflammation of the skin and the composition may be a skin preparation for external use.

Abstract: A method for producing an artificial sebum film is provided with in raw material component and relative ratio, 78.4%-2% of triglyceride, 1%-15% of wax and ester, 20%-35% of squalane, 0.1%-7% of free fatty acid, 0.1%-6% of phospholipid, 0.1%-10% of cholesterol ester, 0.1%-10% of cholesterol, 0.1%-10% of antioxidant and 0.1%-5% of cellular activity regulator. The invention modifies the proportion of raw material composition of the artificial sebum film to reduce the negative effect generated by oxidation, and increase the proportion of squalane, so that the skin under high pollution can restore to the normal equilibrium state. Further, antioxidants and cellular active regulators are added to prolong the oxidation time of artificial sebum film and replenish the adenosine triphosphate in the cells.

Abstract: Methods and compositions for the biological repair of cartilage using a hybrid construct combining both an inert structure and living core are described. The inert structure is intended to act not only as a delivery system to feed and grow a living core component, but also as an inducer of cell differentiation. The inert structure comprises concentric internal and external and inflatable/expandable balloon-like bio-polymers. The living core comprises the cell-matrix construct comprised of HDFs, for example, seeded in a scaffold. The method comprises surgically removing a damaged cartilage from a patient and inserting the hybrid construct into the cavity generated after the foregoing surgical intervention. The balloons of the inert structure are successively inflated within the target area, such as a joint, for example. Also disclosed herein are methods for growing and differentiating human fibroblasts into chondrocyte-like cells via mechanical strain.

Abstract: A device to fabricate a solid freeform fabrication object includes a flattening device to lay powder to form a powder layer and flatten a surface of the powder layer, a liquid fabrication application device to apply a liquid fabrication to the powder layer to fabricate a layer object, a fabrication controller to control fabrication of the solid freeform fabrication object by repeating laying the powder to form a powder layer, flattening the surface of the powder layer, and applying the liquid fabrication to the powder layer to laminate the layer object to fabricate the solid freeform fabrication object, and a detector to detect humidity. The fabrication controller changes at least one of the moving speed of the flattening device, the number of rotation of the flattening device, the application amount of the liquid fabrication, and the lamination pitch according to the humidity detected by the detector.

Abstract: To obtain a lifestyle-related disease therapeutic water which comprises a very small amount of anionized silver, nanosized gold, and 99.9% or more of water. A lifestyle-related disease therapeutic water comprising with respect to one liter of water (a), 3-15 mg in silver equivalent of thiosulfate silver ion (b), and 0.1-0.5 mg in gold equivalent of colloidal gold (c).

Abstract: Provided herein are compositions, methods and uses of humanin or a humanin analog, for example, in treating a subject with humanin or a humanin analog, in part, to reduce, decrease, or inhibit cardiotoxicity caused or induced by an anti-cancer or anti-tumor therapeutic agent, or to protect or preserve cardiac function in the presence of an anti-tumor or anti-cancer therapeutic agent. In some aspects, humanin or humanin analogs, alone or in combination with another cardioprotective agent such as Dexrazoxane are used in combination with a chemotherapeutic agent to treat a hyperproliferative disease or disorder.

Abstract: Formulations for oral transmucosal compositions that include aromatase inhibitors (AIs) in combination with transmucosal absorption enhancers are disclosed. Disclosed oral transmucosal compositions may be for immediate release or slow release, and may be administered to increase bloodstream testosterone levels and thereby reduce symptoms of testosterone deficiency. Disclosed oral transmucosal compositions may include liquid dosage forms, solid dosage forms, and chewing gums. Further dosage forms may include mucoadhesive thin strips, thin films, tablets, patches, and tapes, among others. Other dosage forms may be: mucoadhesive liquids such as gel-forming liquid; gel-forming; semisolids; and gel-forming powders, among other dosage forms that exhibit mucoadhesive properties, and provide oral transmucosal delivery of AIs. Disclosed oral transmucosal compositions may allow the delivery of AIs directly into the patient's bloodstream, thus providing high bioavailability of AIs; therefore, required dose may be lower.

Abstract: The present invention relates to a conjugate or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon receptor agonist, a linker and a hyaluronic acid hydrogel bearing -L1-L2-L-Y—R20 groups, wherein Y represents an GLP-1/Glucagon receptor agonist moiety; and -L is a linker moiety—by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon receptor agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising the conjugates as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon receptor agonist.

Abstract: A method of preventing degeneration of photoreceptor cells in an eye of a mammalian subject includes the step of administering pharmaceutical composition comprising a sulindac agent to the eye of the subject.

Abstract: Methods and compositions for treating bedwetting are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising one or more analgesic agents.

Abstract: A process for preparing a dry powder formulation for inhalation comprising a combination of an anti-cholinergic, a long-acting beta2-adrenoceptor agonist, and a corticosteroid is provided.

Abstract: A printer is configured with at least two printheads that are separated from one another in a cross-process direction by an integral multiple of printhead widths. This configuration enables parallel swaths of material to be ejected and then movement of the printheads in the cross-process direction by a distance corresponding to one or more integral numbers of the printhead width enables the area between the swaths to be completed and the area outside of the original swaths printed.

Abstract: The invention relates to the use of molecularly imprinted polymer(s) or MIPs, of odorous molecule(s), as deodorant agent in particular for selectively trapping molecules that are the cause of human body odour. More particularly by using MIPs which may be obtained via polymerization, preferably via radical polymerization, of a mixture of: i) optionally one or more polymerization initiator(s); ii) one or more functional monomer(s); iii) one or more crosslinking agent(s); and iv) one or more porogenic solvent(s); it being understood that the polymerization a) or b) is performed in the presence v) of one or more “templates” of target molecule(s) responsible for human body odour. Another subject of the invention concerns a process for preparing MIPs as defined previously, MIPs obtained via this process, and a cosmetic composition comprising at least one MIP as defined previously.

Abstract: The present invention is directed to new graft polymer of a hyaluronic acid polymer and N-isopropylacrylamide based polymer, preparations, compositions and uses thereof. In particular, the invention relates to pH and/or thermo-sensitive compositions able to form spontaneously nanoparticles useful as active and agents and delivery systems for at least one bioactive agent.

Abstract: A method of producing a metal-organic framework (MOF) film on a substrate is provided. The method includes providing a substrate having a main surface and forming on the main surface a MOF film using an organometallic compound precursor and at least one organic ligand, wherein each of the organometallic compound precursor and the at least one organic ligand is provided only in the vapour phase.

Abstract: Provided is an agent for preserving a biological component, comprising a hydrogel, the hydrogel comprising a crosslinked product formed from a compound having a plurality of hydroxyl groups and a modified hyaluronic acid having substituents capable of reacting with the hydroxyl groups to form a crosslinked structure.

Abstract: The presently disclosed subject matter provides nitric oxide-releasing polysaccharides and oligosaccharides, in particular, polyglucosamines, and their use in biomedical and pharmaceutical applications. More particularly, in some embodiments, the presently disclosed subject matter provides nitric oxide-releasing polysaccharides and oligosaccharides that release nitric oxide in a controlled and targeted manner, thereby prolonging the therapeutic effects of nitric oxide and improving the specificity of nitric oxide delivery to targeted cells and/or tissues.

Abstract: The present invention includes acidifying film coating compositions containing a polymer and an acidic component for use on orally-ingestible substrates such as tablets and the like. The acidifying coating compositions can be applied as an aqueous dispersion to an enteric-coated substrate to increase the disintegration resistance to aqueous media of up to pH 5.0. In preferred aspects, the acidic component is citric acid, lactic acid, stearic acid or mixtures thereof. Methods of preparing the dry film coatings, methods of preparing corresponding aqueous dispersions, methods of applying the coatings to substrates and the coated substrates themselves are also disclosed.

Abstract: Esterified cellulose ethers which have i) as ester groups aliphatic monovalent acyl groups or a combination of aliphatic monovalent acyl groups and groups of the formula —C(O)—R—COOA wherein R is a divalent aliphatic or aromatic hydrocarbon group and A is hydrogen or a cation, ii) a weight average molecular weight Mw of from 80,000 Dalton to 220,000 Dalton, iii) a Polydispersity Mw/Mn of from 1.3 to 4.0, and iv) an Mz/Mn of not more than 18.5, when the weight average molecular weight Mw, the number average molecular weight Mn and the z-average molecular weight Mz are measured by SEC-MALLS using as mobile phase a mixture produced from 40 parts by volume of acetonitrile and 60 parts by volume of aqueous buffer containing 50 mM NaH2—PO4 and 0.1 M NaNO3. are useful as enteric polymers for pharmaceutical dosage forms.

Abstract: The present application includes stabilized adenovirus compositions comprising an adenovirus and an excipient, wherein the excipient comprises a mixture of dextran and mannitol in amounts effective to maintain at least 40% of the adenovirus activity after spray drying.

Abstract: A method is provided for a novel application of trigger point dry needling. A target tissue is identified based on the observation of a series of movement patterns performed by the patient. Once identified, a needle movement protocol is used to insert a needle into the target tissue to a myofascial trigger point during one or more movement patterns. The needle protocol is adjusted until a local twitch response is induced.

Abstract: Some variations provide an emulsion-colloid system for forming a colloidal barrier material disposed on a substrate, the system comprising a hydrophilic first liquid, an acid, a gelling agent, a hydrophobic second liquid, a plasticizer, and optionally additives, wherein the emulsion-colloid system is characterized by (1) a first instance that is a flowable emulsion above 60° C. and less than the boiling point of the first liquid, and (2) a second instance that is a colloid below 40° C. The emulsion-colloid system is capable of reversible transition, mediated by temperature, between the first instance and the second instance. The disclosed colloidal barrier material provides the functionality of plastic alternatives while removing disadvantages. The disclosed colloidal barrier material reduces labor-intensive application of the barrier, such as the case for covering grain piles with plastic tarps.

Abstract: This disclosure relates to naphthalene-1,8-dicarboxylate ester compounds, lubricating oil base stocks comprising naphthalene-1,8-dicarboxylate ester compounds, lubricating oil compositions comprising such base stocks, and method of making such base stocks. The lubricating oil base stocks comprising naphthalene-1,8-dicarboxylate ester compounds exhibit desirable lubricating properties such as polarity.

Abstract: The present disclosure relates generally to sol-gel polymer composites that comprise chitosan, a hydrophilic polymer, a gelation agent, and optional additional ingredients in a suitable medium. Advantageously, the sol-gel polymer composite can form a durable seal or strong solid in response to one or more physiological stimulus. The disclosure further relates to medical and veterinary uses of the composite, particularly, methods and delivery systems for reducing or preventing the incidence of a mammary disorder in a dairy animal. More particularly, the disclosure includes methods and sol-gel polymer composite compositions for creating a physical barrier on the teat surface or in the teat canal or cistern of a non-human animal for prophylactic treatment of mammary disorders such as mastitis wherein the sol-gel polymer creates a seal in response to one or more physiological stimulus.

Abstract: A particle comprising a first fraction containing an active ingredient and a second fraction containing a surfactant, and having a number average particle diameter of from 1 to 100 nm.

Abstract: Hair cleansing products containing anionic surfactants, amphoteric surfactants, a mixture of specific linear alkanes and a non-polymeric structuring agent, suitable for the cleansing and nourishing of hair, in particular in order to improve the wet and dry combability, the detangling capability, the feel, and the shine of hair.

Abstract: The invention relates to an oral formulation for targeted delivery of cholestyramine to the colon, comprising a plurality of cholestyramine pellets that are coated with a diffusion-controlled inner coating and an enteric outer coating. The invention also relates to the use of this formulation in the treatment of bile acid malabsorption.

Abstract: Hair treatment agents containing a mixture of special linear alkanes, an amidoamine and/or a cationized amidoamine, and at least one cationic surfactant (esterquat and/or quaternary ammonium compound) are provided. In one example, the hair treatment agents are suitable for the care of hair, in particular to improve the wet and dry combability, the disentanglement, the hold, and the gloss of hair.

Abstract: A pharmaceutical composition comprising a lipid component, an amphiphilic emulsifier, a polar liquid carrier, and one or more electrolytes, where the amphiphilic emulsifier forms lipid carrying micelles having a lipophilic core comprising the lipid component in the polar liquid carrier, and/or liposomes organized as a lipid bilayer and/or other particle configurations. The pharmaceutical composition is free of hemoglobin and fluorocarbon and can be used for treating ischemic conditions with reduced reperfusion injury.